Cephalosporins - Orals
| Product | Pharmacopeia | US DMF | EDMF | COS | Others |
|---|---|---|---|---|---|
| Cefazolin acid(Intermediate) | US | √ | ✕ | ✕ | Applicant part DMF |
| 7-ADCA(Intermediate) | ✕ | √ | ✕ | ✕ | ✕ |
| Cefuroxime Acid(Intermediate) | ✕ | √ | ✕ | ✕ | ✕ |
| CAVA(Intermediate) | ✕ | √ | ✕ | ✕ | ✕ |
| Cefalexin | USP/EP/BP/JP | √ | √ | √ | Applicant part DMF as per COS |
| Cefadroxil | USP/EP/BP/JP | √ | √ | √ | Applicant part DMF as per COS |
| Cefradine | USP/EP / BP | ✕ | √ | √ | Applicant part DMF as per COS |
| Cefixime | USP/EP / BP | √ | √ | √ | Canada DMF/JDMF/Applicant part DMF as per COS |
| Cefuroxime Axetil (Amorphous) Chemical | USP/EP / BP | √ | √ | √ | Applicant part DMF as per COS |
| Cefuroxime Axetil (Amorphous) Enzymatic | USP / EP/BP/JP | ✕ | √ | √ | Applicant part DMF as per COS |
| Cefuroxime Axetil (Crystalline) | USP / EP | √ | √ | ✕ | ✕ |
| Cefuroxime Axetil (Crystalline)(Enzymatic)(For Ranbaxy) | USP/EP | √ | √ | ✕ | ✕ |
| Cefprozil | USP/EP | √ | √ | ✕ | ✕ |
| Cefditoren Pivoxil (Amorphous) | In-house/USP/JP | √ | ✕ | ✕ | Applicant part DMF |
| Cefdinir(FORM -A) | USP / JP | ✕ | ✕ | ✕ | JDMF |
| Cefdinir(FORM -B) | USP | √ | ✕ | ✕ | ✕ |
| Cefpodoxime Proxetil | USP / EP / JP | √ | √ | ✕ | JDMF |
| Cefepime Hydrochloride | USP | √ | ✕ | ✕ | ✕ |
| Ceftibuten | In-house/JP | ✕ | ✕ | ✕ | TIP/DMF |
| Cefcapene Pivoxil Hydrochloride | In-house/JP | - | - | ✕ | TIP |
| Ceftamet Pivoxil | In-house/JP | - | - | ✕ | ✕ |
| US DMF-US Drug Master File |
| COS- Certificate of Suitability |
| USP- United States Pharmacopeia |
| JP- Japanese Pharmacopeia |
| TIP- Technical Information Package |
| EP- European Pharmacopeia |
| BP- British Pharmacopeia |
| EDMF- European Drug Master File |
| JDMF - Japan Drug Master File |
Disclaimer
Product exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute as an offer for sales in territories where it is not permitted by law.